Hofstadler G, Schmitt K, Tulzer G, Binder L, Brandstetter B
Landeskinderklinik Linz, Linz, Austria.
AIDS Patient Care STDS. 1998 Sep;12(9):677-80. doi: 10.1089/apc.1998.12.677.
Complications of Bacillus Calmette-Guerin (BCG) vaccination have been reported in immunocompetent as well as in immunocompromised individuals. Severe and/or late complications have been associated with impairment of cell-mediated immunity. A case of BCG lymphadenitis in a vertically infected HIV-positive boy 9.5 years after vaccination is presented. The vaccination was performed within the first week of life, the HIV status of the mother being unknown. When the boy was 2.5 years old, his HIV infection was diagnosed after his mother had died from AIDS. At that time his CD4 count was 739 cells/microL. In the course of the following years, his CD4 count declined steadily, until it reached a low of about 20 cells/microL at the age of 5.5 years. He was troubled with recurring respiratory infections and one incidence of severe pancreatitis. Apart from that, he was in stable condition and led a more or less normal life. At the age of 9.5 years he developed lymphadenitis in his left axilla. The node was examined via biopsy, and the appropriate tests showed an infection with Mycobacterium bovis BCG variety. The CD4 count at that time was 16 cells/microL, polymerase chain reaction showed 220,000 RNA copies/mL. There were no signs of dissemination. Antitubercular agents were administered, and an antiretroviral combination therapy was started. The patient was discharged from the hospital after approximately 2 months. After an uneventful period of 9 months, the boy, still on antitubercular medicine, exhibited a secreting fistula in his left axilla, again due to Mycobacterium bovis, BCG variety. The fistulous tissue was removed surgically, and the antitubercular treatment was given intravenously for almost 3 months before being changed to an oral application. In addition, the antiretroviral regimen was completely exchanged. The case presented illustrates that there is a risk of very late complications in HIV-infected individuals, even when they are vaccinated when they are asymptomatic newborns. Although the risk seems low, one has to be aware of the problem because timely treatment is probably essential to prevent dissemination of the infection. Late complications of BCG vaccinations are most likely to be detected in countries with high medical standards, where HIV-infected children are surviving for longer periods of time.
卡介苗(BCG)接种的并发症在免疫功能正常和免疫功能低下的个体中均有报道。严重和/或晚期并发症与细胞介导免疫受损有关。本文介绍了一名垂直感染的HIV阳性男孩在接种疫苗9.5年后发生卡介苗淋巴结炎的病例。疫苗接种在出生后的第一周内进行,母亲的HIV感染状况未知。当男孩2.5岁时,在其母亲死于艾滋病后,他被诊断出感染了HIV。当时他的CD4细胞计数为739个/微升。在接下来的几年里,他的CD4细胞计数稳步下降,直到5.5岁时降至约20个/微升的低点。他反复出现呼吸道感染,并发生过一次严重的胰腺炎。除此之外,他病情稳定,过着或多或少正常的生活。9.5岁时,他左侧腋窝出现淋巴结炎。通过活检对该淋巴结进行了检查,适当的检测显示感染了牛分枝杆菌卡介苗菌株。当时的CD4细胞计数为16个/微升,聚合酶链反应显示RNA拷贝数为220,000/毫升。没有播散的迹象。给予抗结核药物治疗,并开始抗逆转录病毒联合治疗。大约2个月后患者出院。在经历了9个月的平稳期后,仍在服用抗结核药物的男孩左侧腋窝再次出现因牛分枝杆菌卡介苗菌株引起的分泌性瘘管。手术切除了瘘管组织,抗结核治疗静脉给药近3个月后改为口服。此外,完全更换了抗逆转录病毒治疗方案。本文介绍的病例表明,HIV感染个体即使在无症状新生儿期接种疫苗,也存在发生非常晚期并发症的风险。尽管风险似乎较低,但必须意识到这个问题,因为及时治疗可能对预防感染播散至关重要。卡介苗接种的晚期并发症最有可能在医疗水平较高的国家被发现,在这些国家,感染HIV的儿童存活时间更长。